Aug 12, 2021 / 03:35PM GMT
Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst
Hi, everyone. I'm Gary Nachman, the biopharma analyst at BMO. And we're very excited to have the management team from 9 Meters with us, John Temperato, President and CEO; and Patrick Griffin, who is dialed in, Chief Medical Officer. 9 Meters has a very robust pipeline in GI, targeting rare diseases like short bowel syndrome, but also much larger markets like celiac disease. So really thrilled to have both of you here to discuss some of the exciting programs that you're working on.
John Temperato - 9 Meters Biopharma, Inc. - President, CEO & Director
Thanks, Gary. We're happy to be here.
Questions and Answers:
Gary Jay Nachman - BMO Capital Markets Equity Research - AnalystGreat to have you. Okay. So we only have 20 minutes, a lot to cover. So start with short bowl syndrome, which we'll be calling SBS. So the current unmet needs for those patients and how your lead product, vurolenatide, could potentially provide a substantial benefit for these
Trustpilot
